Search results for "Theria"

showing 10 items of 94 documents

Immunogenicity and reactogenicity of acellular pertussis booster vaccines in children: standard pediatric versus a reduced-antigen content formulatio…

2008

Booster vaccination with a reduced-antigen-content dTpa, pediatric DTPa or adult Td vaccine in DTPa-primed children aged 4-6 years was evaluated. Immunogenicity and CMI was assessed one month and 3.5 years after vaccination. Symptoms were solicited for 15 days post-vaccination. There were no differences between groups in diphtheria or tetanus seroprotection or pertussis vaccine-response rates. Anti-diphtheria and anti-PRN concentrations were higher after DTPa, but groups differences reduced over time. Non-significant trends toward reduced reactogenicity of dTpa were observed. Many factors influence vaccine choice at pre-school age. The dTpa vaccine was as immunogenic and possibly better tol…

MaleWhooping Coughanimal diseasesImmunologyImmunization Secondarycomplex mixturesVaccines AcellularAntigenGermanymedicineHumansGeneral Pharmacology Toxicology and PharmaceuticsChildPertussis VaccineAntigens BacterialReactogenicityBooster (rocketry)TetanusTetanusbusiness.industryDiphtheriaImmunogenicityDiphtheriarespiratory systemmedicine.diseaseAntibodies BacterialVaccinationChild PreschoolImmunologycardiovascular systemFemalebusinessAcellular pertussiscirculatory and respiratory physiologyHuman vaccines
researchProduct

Effect of duration of breastfeeding on neuropsychological development at 10 to 12years of age in a cohort of healthy children

2012

Aim The aim of this article was to explore the effect of duration of breastfeeding on neurocognitive development. Method The long-term effect of breastfeeding on neurodevelopment was examined through a battery of neuropsychological tests in 1403 children (693 females, 710 males; mean age 11y 9mo [SD 6mo], range: 10y 3mo-12y 8mo) who were originally recruited at 6 to 12weeks of age for a clinical trial on acellular pertussis vaccines. An estimated IQ was obtained from scores of the vocabulary, similarities, block design, and coding tests. Breastfeeding data had been prospectively collected throughout the first year of life. Duration of exclusive breastfeeding was defined as the time during w…

MaleWritingIntelligenceLongitudinal StudieSettore M-PSI/04 - Psicologia Dello Sviluppo E Psicologia Dell'EducazioneDevelopmental NeuroscienceChildDose-Response Relationship DrugSettore M-PSI/02 - Psicobiologia E Psicologia FisiologicaThimerosalPreservatives PharmaceuticalInfantTime and Motion StudieEducational StatuBreast FeedingItalyReadingDiphtheria-Tetanus-acellular Pertussis VaccinePediatrics Perinatology and Child HealthFemaleNeuropsychological TestNeurology (clinical)Cohort StudiePsychometricHumanWechsler Scale
researchProduct

Immunogenicity of a combination vaccine containing diphtheria toxoid, tetanus toxoid, three-component acellular pertussis, hepatitis B, inactivated p…

2011

Two randomized trials of 13-valent pneumococcal conjugate vaccine (PCV13) relative to PCV7 evaluated the immune responses of coadministered antigens comprising Infanrix(®) hexa/Infanrix(®)-IPV+Hib (diphtheria, tetanus, 3-component acellular pertussis, hepatitis B, inactivated poliovirus, and Haemophilus influenzae type b). After the 3-dose infant series, immunogenic noninferiority was demonstrated for all concomitantly administered antigens between the PCV13 and PCV7 groups. All antigens elicited good booster responses after the toddler dose except pertussis toxoid; however, 99.6% subjects achieved pertussis toxoid protective antibody level ≥5EU/mL in both groups. These results support the …

Malemedicine.disease_causeAntibodies ViralDiphtheria-Tetanus-acellular Pertussis Vaccinescomplex mixturesPneumococcal conjugate vaccineDrug Administration SchedulePneumococcal VaccinesAntigenDouble-Blind MethodGermanymedicineHumansHepatitis B VaccinesVaccines CombinedDiphtheria-Tetanus-Pertussis VaccineHaemophilus VaccinesVaccines ConjugateGeneral VeterinaryGeneral Immunology and MicrobiologybiologyTetanusbusiness.industryDiphtheriaPoliovirusImmunogenicityPublic Health Environmental and Occupational HealthInfantHepatitis Bmedicine.diseaseVirologyAntibodies BacterialPoliovirus Vaccine InactivatedInfectious DiseasesTreatment OutcomeSpainbiology.proteinMolecular MedicineFemaleAntibodybusinessmedicine.drugVaccine
researchProduct

Effects of prophylactic ibuprofen and paracetamol administration on the immunogenicity and reactogenicity of the 10-valent pneumococcal non-typeableH…

2016

ABSTRACT Prophylactic paracetamol administration impacts vaccine immune response; this study (www.clinicaltrials.gov: NCT01235949) is the first to assess PHiD-CV immunogenicity following prophylactic ibuprofen administration. In this phase IV, multicenter, open-label, randomized, controlled, non-inferiority study in Romania (November 2010–December 2012), healthy infants were randomized 3:3:3:1:1:1 to prophylactically receive immediate, delayed or no ibuprofen (IIBU, DIBU, NIBU) or paracetamol (IPARA, DPARA, NPARA) after each of 3 primary doses (PHiD-CV at age 3/4/5 months co-administered with DTPa-HBV-IPV/Hib at 3/5 and DTPa-IPV/Hib at 4 months) or booster dose (PHiD-CV and DTPa-HBV-IPV/Hib…

Malemedicine.medical_specialtyAntipyreticsparacetamolImmunologyIbuprofenBooster doseDiphtheria-Tetanus-acellular Pertussis Vaccinesmedicine.disease_causeGastroenterologyHaemophilus influenzaePneumococcal Vaccines03 medical and health sciences0302 clinical medicinevaccine030225 pediatricsInternal medicinemedicineHumansImmunology and Allergy030212 general & internal medicineAntipyretic10-valent pneumococcal conjugateAcetaminophenfeverPharmacologyReactogenicityRomaniabusiness.industryIncidenceorganic chemicalsImmunogenicityInfantIbuprofenResearch PapersAntibodies BacterialHealthy VolunteersAcetaminophenVaccinationTreatment OutcomeImmunologyFemaleprophylaxisbusinessmedicine.drugHuman Vaccines & Immunotherapeutics
researchProduct

Immunity to diphtheria in the 3–19 year age group in Italy

1991

In Italy, immunization with diphtheria toxoid has been compulsory for all newborns since 1939. The last two clinical cases of diphtheria were reported in 1987. During the period 1987-1989, immunity against diphtheria was assessed by neutralization test in a random sample of 1740 healthy subjects 3-19 years old, from five geographical areas of Italy. Of the total population, 76.5% showed antibody levels considered to be protective (greater than or equal to 0.1 IU ml-1), 17.2% had a relative degree of protection (0.01-0.09 IU ml-1), and 6.3% lacked immunity (less than 0.01 IU ml-1). The percentage of unprotected subjects increased from 6.1% in the age group of 3-5 years to 11.4% in the age gr…

Malemedicine.medical_specialtyDiphtheria ToxoidBooster doseDisease OutbreaksNeutralization TestsImmunityEpidemiologyHumansMedicineChildDiphtheria toxinGeneral VeterinaryGeneral Immunology and Microbiologybusiness.industryCorynebacterium diphtheriaeIncidenceDiphtheriaIncidence (epidemiology)Public Health Environmental and Occupational HealthDiphtheriaOdds ratiomedicine.diseaseAntibodies BacterialConfidence intervalInfectious DiseasesItalyChild PreschoolImmunologyMolecular MedicineFemalebusinessDemographyVaccine
researchProduct

Booster vaccination with hexavalent DTPa-HBV-IPV/Hib vaccine in the second year of life is as safe as concomitant DTPa-IPV/Hib + HBV administered sep…

2003

The safety and reactogenicity of a booster dose of GSK Biologicals' hexavalent DTPa-HBV-IPV/Hib vaccine (N=4725) was compared with the separate administration of GSK Biologicals' DTPa-IPV/Hib and HBV vaccines (N=4474) in two open, randomized multicenter studies (A and B). Solicited symptoms occurring within 4 days of vaccination were recorded on diary cards and serious adverse events (SAEs) were collected throughout the study period. In Study A (N=1149), incidences of solicited symptoms were similar in both groups; there were no SAEs either reported within 4 days of vaccination or considered to be causally related to vaccination. In study B (N=8050), where fever was the only solicited sympt…

Malemedicine.medical_specialtyFeverImmunization SecondaryBooster dosemedicine.disease_causecomplex mixturesInternal medicineConfidence IntervalsHumansMulticenter Studies as TopicMedicineHepatitis B VaccinesVaccines CombinedAdverse effectDiphtheria-Tetanus-Pertussis VaccineImmunization ScheduleHaemophilus VaccinesRandomized Controlled Trials as TopicHepatitis B virusBooster (rocketry)ReactogenicityGeneral VeterinaryGeneral Immunology and Microbiologybusiness.industryPublic Health Environmental and Occupational HealthInfantVaccinationPoliovirus Vaccine InactivatedInfectious DiseasesHib vaccineImmunizationImmunologyMolecular MedicineFemalebusinessVaccine
researchProduct

Assessment of nine candidate DTP-vaccines with reduced amount of antigen and/or without adjuvant as a fourth (booster-) dose in the second year of li…

2006

Abstract Background The incidence of local reactions to diphtheria-, tetanus and acellular pertussis (DTaP-) vaccines in infants and toddlers increases with each subsequent dose, and entire thigh swellings (ETS) have been reported. Lowering the amount of antigen or of adjuvant may decrease the reactogenicity of DTaP while maintaining a protective immune response. Objectives Following priming with three doses of a DTaP vaccine during infancy, the safety, reactogenicity and immunogenicity of nine different candidate DTaP-vaccines with reduced amounts of antigen and/or adjuvant given as fourth (booster) dose were evaluated. Methods Study participants were healthy infants aged 15–27 months at t…

Malemedicine.medical_specialtymedicine.medical_treatmentDose-Response Relationship ImmunologicImmunization SecondaryBooster doseDiphtheria-Tetanus-acellular Pertussis VaccinesAdjuvants ImmunologicDouble-Blind MethodAntigenInternal medicineHumansMedicineAntigens BacterialReactogenicityGeneral VeterinaryGeneral Immunology and Microbiologybusiness.industryTetanusImmunogenicityDiphtheriaPublic Health Environmental and Occupational HealthInfantmedicine.diseaseVaccinationInfectious DiseasesChild PreschoolImmunologyMolecular MedicineFemalebusinessAdjuvantVaccine
researchProduct

Comparative effects of carrier proteins on vaccine-induced immune response

2011

The efficacy of vaccines against major encapsulated bacterial pathogens -Neisseria meningitidis, Streptococcus pneumoniae, and Haemophilus influenzae type b (Hib) - has been significantly enhanced by conjugating the respective polysaccharides with different carrier proteins: diphtheria toxoid; non-toxic cross-reactive material of diphtheria toxin(197), tetanus toxoid, N. meningitidis outer membrane protein, and non-typeable H. influenzae-derived protein D. Hib, meningococcal, and pneumococcal conjugate vaccines have shown good safety and immunogenicity profiles regardless of the carrier protein used, although data are conflicting as to which carrier protein is the most immunogenic. Coadmini…

Meningococcal Vaccineschemical and pharmacologic phenomenamedicine.disease_causecomplex mixturesMicrobiologyPneumococcal VaccinesImmune systemAdjuvants ImmunologicConjugate vaccineStreptococcus pneumoniaemedicineHumansHaemophilus VaccinesDiphtheria toxinVaccines ConjugateGeneral VeterinaryGeneral Immunology and MicrobiologyChemistryNeisseria meningitidisImmunogenicityPolysaccharides BacterialPublic Health Environmental and Occupational HealthToxoidVaccine efficacyVirologyInfectious DiseasesMolecular MedicineCarrier ProteinsVaccine
researchProduct

Induction of immunologic memory following primary vaccination with the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate …

2011

Background Induction of immunologic memory was assessed following primary vaccination with 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV). Methods Infants were randomized (1:1) to receive 3 doses of PHiD-CV or 7vCRM (7-valent CRM197-conjugated pneumococcal conjugate vaccine [PCV]) at 2, 3, and 4 months of age followed by 23-valent pneumococcal polysaccharide vaccine (23vPS) booster dose at 11 to 14 months of age. Pneumococcal geometric mean antibody concentrations (GMCs) and opsonophagocytic activity (OPA) geometric mean titers were measured. Results Postprimary immune responses were consistent with those in previous PHiD-CV and 7vCRM studies…

Microbiology (medical)Heptavalent Pneumococcal Conjugate VaccineImmunization SecondaryBooster dosemedicine.disease_causecomplex mixturesPneumococcal conjugate vaccinePneumococcal InfectionsHaemophilus influenzaePneumococcal VaccinesConjugate vaccinemedicineHeptavalent Pneumococcal Conjugate VaccineHumansHepatitis B VaccinesVaccines CombinedDiphtheria-Tetanus-Pertussis VaccineImmunization ScheduleHaemophilus VaccinesVaccines Conjugatebusiness.industryVaccinationInfantOpsonin ProteinsPneumococcal polysaccharide vaccineAntibodies BacterialVaccinationPoliovirus Vaccine InactivatedInfectious DiseasesStreptococcus pneumoniaeTreatment OutcomeImmunizationPediatrics Perinatology and Child HealthImmunologybusinessImmunologic Memorymedicine.drugThe Pediatric infectious disease journal
researchProduct

Immunogenicity of routinely used childhood vaccines when coadministered with the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D…

2009

Background The choice of non-typeable Haemophilus influenzae Protein D as main carrier protein in the candidate 10-valent pneumococcal conjugate vaccine (PHiD-CV, GlaxoSmithKline Biologicals), was driven in part to avoid carrier-mediated suppression and possible bystander interference with coadministered vaccines. Immunogenicity data from 3 primary and 2 booster vaccination studies were assessed for possible impacts of PHiD-CV coadministration on immune responses to routinely administered childhood vaccines, in comparison to 7-valent pneumococcal conjugate vaccine (7vCRM) coadministration. Methods Randomized, controlled studies in which PHiD-CV or 7vCRM vaccines were coadministered with DTP…

Microbiology (medical)Heptavalent Pneumococcal Conjugate VaccineLipoproteinsImmunization SecondaryMeningococcal VaccinesBooster dosemedicine.disease_causeAntibodies Viralcomplex mixturesPneumococcal conjugate vaccineHaemophilus influenzaePneumococcal VaccinesBacterial ProteinsConjugate vaccineHeptavalent Pneumococcal Conjugate VaccineMedicineHumansHepatitis B VaccinesVaccines CombinedDiphtheria-Tetanus-Pertussis VaccineImmunization ScheduleHaemophilus VaccinesRandomized Controlled Trials as TopicVaccines Conjugatebusiness.industryImmunization ProgramsDiphtheriaImmunogenicityVaccinationInfantImmunoglobulin Dmedicine.diseaseVirologyAntibodies BacterialVaccinationPoliovirus VaccinesInfectious DiseasesTreatment OutcomePediatrics Perinatology and Child HealthImmunologybusinessCarrier Proteinsmedicine.drugThe Pediatric infectious disease journal
researchProduct